NASDAQ:OCGN Ocugen (OCGN) Stock Price, News & Analysis $0.74 -0.02 (-2.31%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.19%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ocugen Stock (NASDAQ:OCGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ocugen alerts:Sign Up Key Stats Today's Range$0.73▼$0.8050-Day Range$0.70▼$1.0952-Week Range$0.69▼$2.73Volume5.83 million shsAverage Volume7.50 million shsMarket Capitalization$250.82 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Ocugen, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases and other eye conditions. Its approach includes modifier gene therapies designed to address multiple genetic causes of disease, rather than targeting a single mutation. The company’s clinical programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease. These programs are investigational and are not approved treatments. Ocugen has also pursued vaccine development. It previously partnered with Bharat Biotech to seek authorization for Covaxin, a COVID-19 vaccine, in the United States and Canada. The company is based in Malvern, Pennsylvania, and its development activities are primarily focused on the U.S. market.AI Generated. May Contain Errors. Read More Ocugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreOCGN MarketRank™: 1.63566739606 of 5 starsOcugen scored higher than 33% of companies evaluated by MarketBeat, and ranked 1447th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingOcugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOcugen has a consensus price target of $9.50, representing about 1,185.2% upside from its current price of $0.74.Amount of Analyst CoverageOcugen has only been the subject of 1 research reports in the past 90 days.Read more about Ocugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocugen are expected to decrease in the coming year, from ($0.24) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.04% of the float of Ocugen has been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Ocugen has recently increased by 0.48%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.83 News SentimentOcugen has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ocugen this week, compared to 6 articles on an average week.Search InterestOnly 11 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows8 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,088,801.00 in company stock.Percentage Held by Insiders3.95% of the stock of Ocugen is held by insiders.Percentage Held by Institutions10.27% of the stock of Ocugen is held by institutions.Read more about Ocugen's insider trading history. Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCGN Stock News HeadlinesOcugen Stock Gets Stronger EPS Forecast from Noble FinancialNovember 15, 2026 | americanbankingnews.comOcugen Inc. stock rises Wednesday, still underperforms marketNovember 11, 2026 | marketwatch.comA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 19 at 1:00 AM | Concord Gold Capital (Ad)Ocugen Signs Regional OCU400 Licensing Deal; Potential Payments Reach $7.1 MlnNovember 10, 2026 | rttnews.comOcugen inks licensing deal with Australia’s Celairis for gene therapyNovember 10, 2026 | msn.comOcugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEANNovember 10, 2026 | globenewswire.comH.C. Wainwright Remains a Buy on Ocugen (OCGN)November 8, 2026 | theglobeandmail.comHC Wainwright Issues Optimistic Estimate for Ocugen EarningsNovember 8, 2026 | americanbankingnews.comSee More Headlines OCGN Stock Analysis - Frequently Asked Questions How have OCGN shares performed this year? Ocugen's stock was trading at $1.35 at the beginning of the year. Since then, OCGN shares have decreased by 45.2% and is now trading at $0.7392. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company earned $1.49 million during the quarter, compared to the consensus estimate of $889 thousand. Read the conference call transcript. When did Ocugen IPO? Ocugen (OCGN) raised $83 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 5,909,091 shares at $13.00-$15.00 per share. Who are Ocugen's major shareholders? Ocugen's top institutional investors include State Street Corp (5.76%), Goldman Sachs Group Inc. (0.98%), Marshall Wace LLP (0.49%) and Profund Advisors LLC (0.05%). Insiders that own company stock include Shankar Musunuri, Treerita Essali Johnson-Greene and Prabhavathi Fernandes. View institutional ownership trends. How do I buy shares of Ocugen? Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocugen investors own include NIO (NIO), Tesla (TSLA), AMC Entertainment (AMC), Palantir Technologies (PLTR), SNDL (SNDL), NVIDIA (NVDA) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/06/2026Today11/19/2026AGM 202612/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OCGN's financial health is in the Red zone, according to TradeSmith. OCGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OCGN CIK1372299 Webocugen.com Phone(484) 328-4701Fax781-547-4452Employees116Year Founded2013Price Target and Rating Average Price Target for Ocugen$9.50 High Price Target$11.00 Low Price Target$7.00 Potential Upside/Downside+1,185.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.85 million Net MarginsN/A Pretax Margin-1,367.61% Return on Equity-127,987.80% Return on Assets-98.50% Debt Debt-to-Equity Ratio4.17 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$4.78 million Price / Sales52.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-14.78Miscellaneous Outstanding Shares339,307,000Free Float325,904,000Market Cap$250.82 million OptionableOptionable Beta2.04 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:OCGN) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.